论文部分内容阅读
AIM:The beneficial effect of zinc supplementation onthe efficacy of interferon as a treatment for chronichepatitis C had been demonstrated in hepatitis virusgenotype 1b of high viral load.This study focusedon patients with genotype 2,which is more sensitiveto interferon than genotype 1b,and used consensusinterferon(CIFN)with or without zinc.METHODS:We randomized 83 patients with chronichepatitis C to CIFN at 18 MIU six times/wk for 4 wk,followed by CIFN at 18 MIU six times/wk for another 20wk,in combination with polaprezinc 300 mg(regimen A,n=41)or as monotherapy(regimen B,n=42).Thirty-one patients in regimen A and 33 patients in regimenB completed the clinical trial;the remaining patientswithdrew because of side effects or a transfer to anotherhospital.RESULTS:Sustained biochemical response,defined asa normal aminotransferase level at the end of the 6-mopost-treatment observation,was 68% and 69%,andsustained virological response,defined as undetectableHCV-RNA at the end of the 6-mo post-treatmentobservation,was 54% and 67% for regimens A and B,respectively.CONCLUSION:CIFN treatment combined with zinc didnot enhance the effect of CIFN as shown by biochemical,virological criteria.No side effects related to polaprezincwere noted.
AIM: The beneficial effect of zinc supplementation on the efficacy of interferon as a treatment for chronic hepatitis C had been demonstrated in hepatitis virus genotype 1b of high viral load. This study focused on patients with genotype 2, which is more sensitive to interferon than genotype 1b, and used consensusinterferon (CIFN) with or without zinc. METHODS: We randomized 83 patients with chronic hepatitis C to CIFN at 18 MIU six times / wk for 4 weeks, followed by CIFN at 18 MIU six times / wk for another 20 weeks, in combination with polaprezinc 300 mg (regimen A, n = 41) or as monotherapy (regimen B, n = 42). Thirty-one patients in regimen A and 33 patients in regimenB completed the clinical trial; the remaining patientswithdrew because of side effects or a transfer to another hospital. RESULTS: Sustained biochemical response, defined asa normal aminotransferase level at the end of the 6-mopost-treatment observation, was 68% and 69%, and sustained virological response, defined as undetectable HCV-RNA at the end of the 6-mo po st-treatmentobservation, was 54% and 67% for regimens A and B, respectively.CONCLUSION: CIFN treatment combined with zinc didnot enhance the effect of CIFN as shown by biochemical, virological criteria. No side effects related to polaprezincwere noted.